Endocrine and metabolic changes in epileptic patients receiving valproic acid (Q36142002)

12 August 2017

1 reference

title

Endocrine and metabolic changes in epileptic patients receiving valproic acid (English)

1 reference

12 August 2017

Alberto Verrotti

1

1 reference

12 August 2017

Rita Greco

series ordinal

2

1 reference

12 August 2017

Giuseppe Latini

series ordinal

3

1 reference

12 August 2017

Francesco Chiarelli

series ordinal

4

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Journal of Pediatric Endocrinology and Metabolism

12 August 2017

published in

1 reference

12 August 2017

volume

18

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

423-430

1 reference

Risk of excessive weight gain in epileptic children treated with valproate

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Metabolic changes during treatment with valproate in humans: implication for untoward weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Weight gain associated with valproate in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Valproate and mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Serum insulin and leptin levels in valproate-associated obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Insulin resistance in epileptic girls who gain weight after therapy with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Thyroid hormones in epileptic children receiving carbamazepine and valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Valproate-induced hyperammonemic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Valproic acid associated abnormalities of carnitine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

The role of carnitine supplementation during valproic acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Effect of carbamazepine and valproate on bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Moderate exercise during growth in prepubertal boys: changes in bone mass, size, volumetric density, and bone strength: a controlled prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Pubertal arrest associated with valproic acid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Hypothalamic pituitary function testing on children receiving carbamazepine or sodium valproate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

On the association between valproate and polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Is valproate pharmacotherapy associated with polycystic ovaries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

Excretion of Valproic Acid into Semen of Rabbits and Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FJPEM.2005.18.5.423

10.1515/JPEM.2005.18.5.423

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference